In the setting of active surveillance and focal therapy for prostate cancer (PCa), precise localization of the index lesion is crucial to ensure good oncological outcomes. Our objective was to assess the accuracy of multiparametric MRI (mp-MRI) for index lesion localization.
INTRODUCTION AND OBJECTIVES:
In the setting of active surveillance and focal therapy for prostate cancer (PCa), precise localization of the index lesion is crucial to ensure good oncological outcomes. Our objective was to assess the accuracy of multiparametric MRI (mp-MRI) for index lesion localization.
METHODS: We conducted a retrospective bi-centric study including 405 patients operated by radical prostatectomy from 2010 to 2015 and having been assessed preoperatively by mp-MRI in two national referral centres for PCa management.Pre-operative mp-MRI sequences included T2-weighted, diffusion weighted, and dynamic contrast enhanced and were acquired from 1,5 (n¼344) or 3 Tesla (n¼61) with external phased array coils. The MRI index lesion was defined as the lesion with the highest PI-RADS score. The pathological index lesion was defined as the lesion with the greatest Gleason score. If there were multiple lesions with the same PI-RADS or Gleason score, the largest one was considered as the index lesion. A neighbouring method, dividing the prostate in 12 sectors, was applied to determine the concordance between mp-MRI findings and pathology reports for index lesion localization.
RESULTS: Out of the 405 patients, 385 (95%) had an index lesion identified on the mp-MRI and 20 (5%) had a normal mp-MRI. On pathology reports, the Gleason score was 6 in 113 (28%), 7 in 252 (62%) and 8 in 40 (10%) of the patients. The index lesion diameter was greater than 10mm in 336 (83%) patients. For index lesion detection, mp-MRI had a sensitivity of 63%, a specificity of 67% and a positive predictive value of 66%. Increased sensitivity was obtained for larger tumors on mp-MRI (>10mm, 194/275; 71%) and greater biopsy Gleason score tumors (7, 147/202; 73%) . In multivariate analysis, the detection of the index lesion by mp-MRI was significantly improved when the biopsy Gleason score was 7 (4+3) (p¼0.001), the index lesion mp-MRI size was > 10mm (p<0.001) and the prostate weight was 50g (p¼0.017).
CONCLUSIONS: In this contemporary assessment, mp-MRI failed to localize the index lesion in up to 40% of cases. Larger tumor sizes on mp-MRI and higher Gleason scores on biopsy cores were associated with significantly higher sensitivity of mp-MRI for index lesion localization. INTRODUCTION AND OBJECTIVES: MR/US fusion biopsy (FB) is a promising modality for detection of clinically significant prostate cancer (csPCa), defined as Gleason >¼7 in patients who have had a prior negative biopsy. The purpose of this study is to assess the learning curve with adoption of FB using PI-RADS Version 2 (v2) for detecting csPCa and to identify patient and technical factors that predict success.
METHODS: A total of 113 consecutive patients with at least one prior negative biopsy and a multiparametric MRI (mpMRI) exam of the prostate with a PIRADS 3 or greater index lesion underwent FB at a single academic center previously naive to FB technology. Outcomes are detection rates for Gleason 6 cancer, csPCa, and any cancer. The following 22 covariates were analyzed: age, body mass index (BMI), PSA, prostate volume (MRI-estimated), prostate volume (US-estimated), PSAD (MRI-estimated), PSAD (US-estimated), time interval since the last negative SB, number of prior negative systematic biopsies, number of targeted biopsy cores of the index lesion, size of index lesion, PI-RADS v2 score, number of suspicious lesions on mpMRI, institution experience, surgeon, obesity, digital rectal exam (DRE), atypical small acinar proliferation (ASAP) on prior biopsy, highgrade prostatic intraepithelial neoplasia (HGPIN) on prior biopsy, and location of index lesion (zone, region, and sector). Multiple logistic regression with model selection was used to select covariates having significant effects on the outcome. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e23 RESULTS: Prostate cancers were identified in 52% of cases. Among patients diagnosed with prostate cancer, 80% were clinically significant. The detection rates of csPCa using FB when a PIRADS 3, 4, or 5 index lesion was present on mpMRI were 6%, 46%, and 66%, respectively. PI-RADS v2 score had a predictive accuracy (AUC) of 0.79 for csPCa detection. Institutional experience over time, MRI-estimated prostate volume, and PI-RADS v2 score were independent predictors of success at detecting csPCa.
CONCLUSIONS: Since FB is a highly technical and experience-driven process, development of internal quality measures to assess the institutional learning curve and the quality of PI-RADS v2 scoring is critical with adoption of this technology.
Source of Funding: none

MP03-12 ACCURACY OF MULTIPARAMETRIC MR IMAGING WITH PI-RADS V2 ASSESSMENT IN DETECTING INFILTRATIONS OF THE NEUROVASCULAR BUNDLES PRIOR TO PROSTATECTOMY
Markus Sauer*, Julius Weinrich, Georg Salomon, Pierre Tennstedt, Gerhard Adam, Dirk Beyersdorff, Hamburg, Germany INTRODUCTION AND OBJECTIVES: To evaluate mpMRIbased assessments of neurovascular bundle (NVB) infiltration and to determine the value of PI-RADS V2 scores for the prediction of NVBinfiltration before prostatectomy. METHODS: Our institutional review board approved the study. 198 patients underwent standardized mpMRI at 3T prior to surgery, including high resolution T2w-TSE-imaging in 3 planes, T1-w-TSE, DWI with ADC map, PD-TSE and Gd-DCE with post-processing of images. Assessment for NVB-infiltration was made for each side of each prostate (n¼396). Maximum PI-RADS-V2 scores were determined for the posterolateral areas adjacent to the NVB (n¼396). MRI-findings were correlated to pathologic analysis as reference standard, where NVBinfiltration was defined as tumor invasion into the NVB or extraprostatic expansion (EPE) in the posterolateral area adjacent to the NVB.
RESULTS: Overall T-staging accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of mpMRI were 78.3%, 644 %, 892 %, 82.4% and 76.2%, respectively. In 396 cases infiltration of the NVB was predicted with 89.4%, 75.2%, 94.0%, 80.2% and 92.1% overall accuracy, sensitivity, specificity, PPV and NPV, respectively. By correlating 365 maximum PIRADS-V2 scores to the pathology of adjacent NVBs, infiltration was demonstrated in 13 NVBs despite low likelihood of cancer presence (PI-RADS 1 or 2 scores), amounting to 14% false negative predictions.
CONCLUSIONS: mpMRI-based assessment of NVB-infiltration should be acknowledged when nerve sparing surgery is considered. However, areas without tumor suspicion (PI-RADS 1 or 2) might demonstrate NVB-infiltration in pathology causing false negative predictions.
Source of Funding: none
MP03-13 MULTIPARAMETRIC MRI CANNOT PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER OUTSIDE THE INDEX LESION: IMPLICATIONS FOR EXTENDED BIOPSY TEMPLATES
INTRODUCTION AND OBJECTIVES:
There is growing interest on the using of prostate mpMRI for performing targeted biopsies. However, lack of consensus exists whether it is mandatory to perform concomitant systematic biopsies. The aim of this study was to assess the predictors of clinical significant prostate cancer (csPCa) outside the mpMRI detected index lesion (IL) and to assess whether MRI parameters may predict csPCa outside IL.
METHODS: 244 patients underwent mpMRI of the prostate with subsequent biopsy between 2013 and 2016 at a single tertiary referral centre. A 1.5 T mpMRI study using an endorectal coil was performed in all patients. Lesions suggesting of significant PCa visualized on mpMRI, defined as PI-RADS v.2 3, were targeted with cognitive or fusion approach. Furthermore each patient was submitted to standard random biopsy during the same session. csPCa was defined as Gleason Score 7. Multivariable logistic regression analysis (MVA) was performed to assess the predictors of csPCa outside the IL. Covariates consisted of age at biopsy, PSA, prostate volume, digital rectal examination (negative vs. positive), PI-RADS (3 vs. >3), IL volume, number of ILs, number of random cores and previous biopsy (biopsy naive vs. previous negative biopsy vs. previous positive biopsy).
RESULTS: Overall, 46 and 54% of patients were previous biopsied and biopsy naive, respectively. Median PSA, prostate volume, number of random cores, number of ILs, IL volume were 7 ng/ml, 47 cc, 12, 1, 0.70 cc, respectively. The overall detection rate of csPCa outside the IL was 34%. When patients were stratified according to the targeted biopsy results, the detection rate of csPCa outside the IL was 10 and 30% in men with a negative and positive targeted biopsy, respectively. At MVA age (OR: 1.07; p¼0.01), PSA (OR: 1.12; p¼0.01), prostate volume (OR: 0.98; p¼0.02), positive digital rectal examination (OR 3.7; p<0.01) and previous negative biopsy (OR 0.31; p¼0.01) were independent predictors of the presence of overall csPCa outside the IL (AUC: 65%). Conversely, PI-RADS, IL volume, number of ILs detected at mpMRI were not associated with overall detection of csPCa outside the IL (all p0.1).
CONCLUSIONS: mpMRI missed csPCa outside the IL in approximately a third of men. Despite the presence of clinical predictors, neither patient characteristics nor mpMRI data are able to reliably select patients candidate for targeted biopsy alone (AUC: 65%). Therefore, based on our data, systematic biopsies should be always performed in conjunction with targeted biopsy in men with suspected csPCa at mpMRI.
